- Philadelphia and Bucks County Recovery Houses
- In The Rooms
- Recovery Centers America PA
- Day Break Solutions Treatment Pa.
- My Recovery Online meetings
- Recovery Connections You Tube Channel
- Christian Rehab Center locator
- Jade Recovery Veterans Support
- HELP FOR TEENS
- Pregnancy Help Choice One
- ARS All Resource Solutions
- Pro Act Philly
Thursday, July 12, 2012
CDC: One-Third of Prescription Painkiller Overdose Deaths Caused by Methadone
By Join Together Staff | July 9, 2012 | Leave a comment | Filed in Addiction,Drugs, Prescription Drugs & Treatment
Methadone causes 30 percent of prescription painkiller overdose deaths, according to a new report from the Centers for Disease Control and Prevention (CDC). Some doctors are now prescribing methadone to treat chronic problems such as back pain, which is making the drug more widely available.
According to the CDC, methadone and other extended-release opioids should not be used for mild pain, acute pain, “breakthrough” pain, or on an as-needed basis. “For chronic noncancer pain, methadone should not be considered a drug of first choice by prescribers or insurers,” the report noted.
In an effort to cut down on abuse of drugs meant to treat addiction, Titan Pharmaceuticals plans to file for Food and Drug Administration approval for an implant of buprenorphine, which eases withdrawalsymptoms. The Wall Street Journal reports that buprenorphine currently comes in pills or strips, which can be used to get high, or used more heavily than they should be to relieve symptoms of withdrawal. The pills are crushed and then injected or snorted.
The implant, called Probuphine, is inserted just under the skin in the upper arm. It releases continuous, small amounts of the drug over six months. “You cannot easily remove these implants from the arm,” Titan Senior Vice President Katherine L. Beebe told the newspaper.
A study conducted by Titan and published in the Journal of the American Medical Association in 2010 found that among people with opioid dependence, users of Probuphine had significantly less illicit opioid use, and fewer symptoms of withdrawal and craving, compared with those who received a placebo implant.